Da Hee Han, PharmD

TherapeuticsMD announced the launch of Bijuva (estradiol and progesterone) capsules for use in women with a uterus for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.

Gelesis announced that the Food and Drug Administration (FDA) has cleared Plenity (Gelesis100) to aid in weight management for overweight and obese adults, in conjunction with diet and exercise. Available in capsule form, Plenity, a non-systemic, superabsorbent hydrogel, is intended for use in adults with a body mass index (BMI) of 25 to 40 kg/m2…

Sanofi announced plans to expand its ‘insulins Valyou Savings Program’ that will further reduce the cost of Sanofi insulins for patients with diabetes. The Insulins Valyou Savings Program was launched a year ago to set the price for cash-paying patients at $99 for one 10 mL vial or $149 for one box of pens. Now,…

Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2019 in San Diego.

Researchers reported that mean urinary-free cortisol (mUFC) normalization with Recorlev was similar in patients with and without diabetes.

The FDA issued a Complete Response Letter rejecting the New Drug Application (NDA) for Zynquista (sotagliflozin; Sanofi and Lexicon) for the treatment of adults with type 1 diabetes, in combination with insulin.

Apotex announced a voluntary recall of 4 lots of Drospirenone and Ethinyl Estradiol Tablets 3mg/0.03mg due to the possibility of defective blisters with incorrect tablet arrangements and/or empty blister pockets.

Eli Lilly announced plans to launch an authorized generic version of Humalog (insulin lispro) 100 Units/mL at a 50% lower list price.

Eli Lilly announced plans to launch an authorized generic version of Humalog (insulin lispro) 100 Units/mL at a 50% lower list price.

Boehringer Ingelheim and Lilly announced that the CAROLINA trial met its primary endpoint, demonstrating no increased cardiovascular (CV) risk with linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, when compared with glimepiride, a sulfonylurea, in patients with type 2 diabetes and CV risk.